Numerate and Boehringer Ingelheim (Canada) Ltd. Form Research Collaboration Based on in silico Drug Design Technology

Published: Dec 06, 2011

SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a technology platform company that is leveraging the power of cloud computing and novel computational methods to transform the drug design process, announced today that it has entered into a research collaboration with Boehringer Ingelheim (Canada) Ltd. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed infectious disease target.

Back to news